See more : China Shineway Pharmaceutical Group Limited (CSWYY) Income Statement Analysis – Financial Results
Complete financial analysis of Atreca, Inc. (BCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atreca, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Auric Mining Limited (AWJ.AX) Income Statement Analysis – Financial Results
- Kasikornbank Public Company Limited (KBANK.BK) Income Statement Analysis – Financial Results
- Shenzhen CDL Precision Technology Co., Ltd. (300686.SZ) Income Statement Analysis – Financial Results
- Faraday Copper Corp. (CPPKF) Income Statement Analysis – Financial Results
- TISCO Financial Group Public Company Limited (TISCO.BK) Income Statement Analysis – Financial Results
Atreca, Inc. (BCEL)
About Atreca, Inc.
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 770.00K | 851.00K | 1.35M | 2.13M | 0.00 | 0.00 |
| Cost of Revenue | 7.08M | 77.00K | 22.00K | 122.00K | 0.00 | 0.00 |
| Gross Profit | -6.31M | 774.00K | 1.33M | 2.01M | 0.00 | 0.00 |
| Gross Profit Ratio | -819.61% | 90.95% | 98.37% | 94.28% | 0.00% | 0.00% |
| Research & Development | 66.83M | 78.35M | 62.05M | 54.73M | 32.51M | 24.87M |
| General & Administrative | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
| Other Expenses | 770.00K | 851.00K | 1.35M | 2.13M | 961.00K | 1.72M |
| Operating Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
| Cost & Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
| Interest Income | 817.00K | 207.00K | 1.22M | 3.21M | 714.00K | 152.00K |
| Interest Expense | 0.00 | 3.00K | 4.00K | 6.00K | 9.00K | 14.00K |
| Depreciation & Amortization | 7.08M | 4.55M | 2.38M | 1.70M | 1.41M | 1.21M |
| EBITDA | -90.44M | -104.70M | -83.93M | -67.22M | -37.20M | -26.51M |
| EBITDA Ratio | -12,559.48% | -12,837.25% | -6,203.33% | -3,150.14% | 0.00% | 0.00% |
| Operating Income | -103.79M | -113.80M | -86.31M | -68.92M | -39.57M | -29.44M |
| Operating Income Ratio | -13,479.09% | -13,371.92% | -6,379.01% | -3,229.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | 368.00K | 978.00K | 1.19M | 5.09M | 1.63M | 1.91M |
| Income Before Tax | -97.16M | -109.33M | -86.33M | -67.48M | -37.94M | -27.52M |
| Income Before Tax Ratio | -12,617.79% | -12,846.65% | -6,380.93% | -3,162.28% | 0.00% | 0.00% |
| Income Tax Expense | -6.63M | 1.00K | 1.00K | 1.00K | -1.00K | 3.00K |
| Net Income | -90.53M | -109.33M | -86.34M | -67.48M | -37.94M | -27.53M |
| Net Income Ratio | -11,756.49% | -12,846.77% | -6,381.01% | -3,162.32% | 0.00% | 0.00% |
| EPS | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
| EPS Diluted | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
| Weighted Avg Shares Out | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
| Weighted Avg Shares Out (Dil) | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
Why Is Atreca (BCEL) Stock Up 85% Today?
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
3 Penny Stocks to Catapult You Into the Millionaires' Club
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports